Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Long · SciRah

Researcher profile · Semantic Scholar

G. Long

Share profile

G. Long — researcher profile on SciRah

h-index: 126
Works: 754
Citations: 99K

Most-cited papers

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
H. Tawbi, D. Schadendorf, E. Lipson, P. Ascierto +18 more
2022New England Journal of Medicine1,514 citations Open access
Semantic Scholar
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
I. Reijers, A. Menzies, A. V. van Akkooi, J. Versluis +34 more
2022Nature Medicine356 citations Open access
Semantic Scholar
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
J. Chesney, A. Ribas, G. Long, J. Kirkwood +25 more
2022Journal of Clinical Oncology275 citations Open access
Semantic Scholar
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
R. Simpson, E. Shanahan, M. Batten, I. Reijers +26 more
2022Nature Medicine215 citations
Semantic Scholar
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
P. Ascierto, E. Lipson, R. Dummer, J. Larkin +18 more
2023Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
J. Weber, D. Schadendorf, M. Del Vecchio, J. Larkin +32 more
2022Journal of Clinical Oncology140 citations Open access
Semantic Scholar
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
G. Long, M. Carlino, C. McNeil, A. Ribas +15 more
2024Annals of Oncology127 citations
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
G. Long, J. Luke, M. Khattak, L. de la Cruz Merino +20 more
2022The Lancet Oncology127 citations
Semantic Scholar
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
C. Robert, M. Carlino, C. McNeil, A. Ribas +15 more
2023Journal of Clinical Oncology100 citations
Semantic Scholar
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
A. Arance, L. de la Cruz-Merino, T. Petrella, R. Jamal +18 more
2022Journal of Clinical Oncology100 citations
Semantic Scholar
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
G. Long, A. Menzies, R. Scolyer
2023Journal of Clinical Oncology83 citations
Semantic Scholar
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
A. Diab, H. Gogas, S. Sandhu, G. Long +22 more
2023Journal of Clinical Oncology79 citations Open access
Semantic Scholar
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
I. Reijers, Disha Rao, J. Versluis, A. Menzies +22 more
2023Journal of Experimental Medicine78 citations Open access
Semantic Scholar
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
Rachel S. Goodman, A. Lawless, R. Woodford, Faisal Fa'ak +12 more
2023JAMA Network Open72 citations Open access
Semantic Scholar
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
A. Khattak, J. Weber, T. Meniawy, M. Taylor +16 more
2023Journal of Clinical Oncology64 citations
Semantic Scholar
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
P. Bhave, T. Ahmed, S. Lo, A. Shoushtari +43 more
2022Journal for ImmunoTherapy of Cancer63 citations Open access
Semantic Scholar
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
T. El Zarif, A. Nassar, E. Adib, Bailey G Fitzgerald +77 more
2023Journal of Clinical Oncology55 citations Open access
Semantic Scholar
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.
I. Reijers, R. Rawson, A. Colebatch, E. Rozeman +15 more
2022JAMA Surgery50 citations Open access
Semantic Scholar
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
O. Kennedy, M. Kicinski, S. Valpione, S. Gandini +27 more
2022European Journal of Cancer50 citations Open access
Semantic Scholar
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
G. Attrill, C. Owen, T. Ahmed, Ismael A. Vergara +12 more
2022Journal for ImmunoTherapy of Cancer49 citations Open access
Semantic Scholar
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
A. V. van Akkooi, T. Hieken, E. Burton, C. Ariyan +37 more
2022Annals of Surgical Oncology42 citations Open access
Semantic Scholar
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
C. Garbe, R. Dummer, T. Amaral, R. Amaria +22 more
2023Nature Medicine39 citations Open access
Semantic Scholar
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
G. Long, F. Hodi, E. Lipson, D. Schadendorf +16 more
2022Journal of Clinical Oncology35 citations
Semantic Scholar
Association of anti-thyroid antibodies in checkpoint inhibitor associated thyroid immune related adverse events.
C. Muir, Cameron Wood, R. Clifton-Bligh, G. Long +4 more
2022Journal of Clinical Endocrinology and Metabolism33 citations Open access
Semantic Scholar
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
H. Tawbi, C. Robert, J. C. Brase, D. Gusenleitner +11 more
2022Journal for ImmunoTherapy of Cancer29 citations Open access
Semantic Scholar
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
J. Larkin, J. Weber, M. Del Vecchio, H. Gogas +23 more
2022European Journal of Cancer28 citations Open access
Semantic Scholar
Case series: Immune checkpoint inhibitor-induced transverse myelitis
S. Chatterton, Shuo Xi, Jessica Jia, M. Krause +9 more
2023Frontiers in Neurology27 citations Open access
Semantic Scholar
Adjuvant therapy for stage II melanoma: the need for further studies
R. Lee, M. Mandalà, G. Long, A. Eggermont +4 more
2023European Journal of Cancer26 citations Open access
Semantic Scholar
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
P. Serra-Bellver, J. Versluis, H. Oberoi, Cong Zhou +16 more
2022European Journal of Cancer26 citations Open access
Semantic Scholar
Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma
Zarwa Yaseen, T. Gide, J. Conway, A. Potter +5 more
2022Frontiers in Molecular Biosciences25 citations Open access
Semantic Scholar
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
Min-Yu Wang, S. Zadeh, A. Pizzolla, K. Thia +12 more
2022Journal for ImmunoTherapy of Cancer25 citations Open access
Semantic Scholar
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)
G. Long, M. Del Vecchio, J. Weber, C. Hoeller +16 more
2023SKIN The Journal of Cutaneous Medicine24 citations Open access
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
M. Khattak, J. Luke, G. Long, P. Ascierto +20 more
2022European Journal of Cancer23 citations Open access
Semantic Scholar
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
A. Weppler, L. Da Meda, I. Pires da Silva, Wen Xu +12 more
2023European Journal of Cancer21 citations
Semantic Scholar
Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE)
J. Lai-Kwon, Brooke Kelly, S. Lane, R. Biviano +7 more
2022Supportive Care in Cancer21 citations Open access
Semantic Scholar
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
O. Kennedy, M. Kicinski, S. Valpione, S. Gandini +26 more
2023European Journal of Cancer20 citations Open access
Semantic Scholar
Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
F. Dimitriou, A. Hauschild, J. Mehnert, G. Long
2022American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting20 citations
Semantic Scholar
Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.
Hansol Lee, A. Ferguson, Camelia Quek, Ismael A. Vergara +17 more
2023Clinical Cancer Research18 citations Open access
Semantic Scholar
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
P. Bhave, A. Hong, S. Lo, Rebecca Johnson +16 more
2023Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
D. Schadendorf, H. Tawbi, E. Lipson, F. Hodi +11 more
2023European Journal of Cancer18 citations Open access
Semantic Scholar
Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
R. Dummer, C. Robert, R. Scolyer, J. Taube +15 more
2023Cancer Research17 citations
Semantic Scholar
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
S. Wong, Steven M. Blum, Xiao-Peng Sun, I. D. Da Silva +26 more
2022European Journal of Cancer17 citations
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
J. Luke, P. Ascierto, M. Khattak, L. de la Cruz Merino +16 more
2023Journal of Clinical Oncology16 citations
Semantic Scholar
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
H. Tawbi, F. Hodi, E. Lipson, D. Schadendorf +15 more
2023Journal of Clinical Oncology15 citations
Semantic Scholar
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
A. V. van Akkooi, A. Hauschild, G. Long, M. Mandalà +6 more
2023Future Oncology15 citations Open access
Semantic Scholar
Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
K. Nahar, Felix Marsh-Wakefield, R. Rawson, T. Gide +14 more
2022JCI Insight15 citations Open access
Semantic Scholar
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
S. Cass, J. Tobin, Y. D. Seo, G. Gener-Ricos +29 more
2023Annals of Oncology14 citations Open access
Semantic Scholar
Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases
J. Wilmott, H. Tawbi, J. Engh, N. Amankulor +14 more
2022Clinical Cancer Research14 citations Open access
Semantic Scholar
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
S. Moschos, S. Sandhu, K. Lewis, R. Sullivan +7 more
2022Investigational new drugs13 citations Open access
Semantic Scholar
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
G. Long, J. Kirkwood, C. Hoeller, J. Grob +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Menzies×21
Invite
A. Menzies — researcher profile on SciRah
M. Carlino×19
Invite
M. Carlino — researcher profile on SciRah
P. Ascierto×18
Invite
P. Ascierto — researcher profile on SciRah
J. Grob×17
Invite
J. Grob — researcher profile on SciRah

×15

Invite

R. Scolyer — researcher profile on SciRah

D. Schadendorf×14

Invite

D. Schadendorf — researcher profile on SciRah

Invite

C. Blank — researcher profile on SciRah

P. Rutkowski×9

Invite

P. Rutkowski — researcher profile on SciRah

Invite

A. Arance — researcher profile on SciRah

Invite

V. Atkinson — researcher profile on SciRah

Invite

C. Robert — researcher profile on SciRah

Invite

H. Gogas — researcher profile on SciRah